Psoriasis-related juvenile idiopathic arthritis
diseaseOn this page
Also known as JPsAjuvenile psoriatic arthritispsoriasis-related JIA
Summary
Psoriasis-related juvenile idiopathic arthritis (MONDO:0019436) is a disease and 11 clinical trials. Top therapeutic interventions include secukinumab, cravacitinib, and apremilast. A subtype of juvenile idiopathic arthritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Worldwide) [Orphanet-validated]
- Phenotypes (HPO): 29
- Clinical trials: 11
Clinical features
Signs & symptoms
Clinical features (HPO)
29 HPO clinical features (Orphanet curated; top 29 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0011118 | Abnormality of tumor necrosis factor secretion | Very frequent (80-99%) |
| HP:0000989 | Pruritus | Frequent (30-79%) |
| HP:0001369 | Arthritis | Frequent (30-79%) |
| HP:0001803 | Nail pits | Frequent (30-79%) |
| HP:0002829 | Arthralgia | Frequent (30-79%) |
| HP:0002960 | Autoimmunity | Frequent (30-79%) |
| HP:0003493 | Antinuclear antibody positivity | Frequent (30-79%) |
| HP:0003765 | Psoriasiform dermatitis | Frequent (30-79%) |
| HP:0005764 | Polyarticular arthritis | Frequent (30-79%) |
| HP:0031090 | Finger dactylitis | Frequent (30-79%) |
| HP:0031091 | Toe dactylitis | Frequent (30-79%) |
| HP:0040313 | Oligoarthritis | Frequent (30-79%) |
| HP:0100686 | Enthesitis | Frequent (30-79%) |
| HP:0000554 | Uveitis | Occasional (5-29%) |
| HP:0000988 | Skin rash | Occasional (5-29%) |
| HP:0001376 | Limitation of joint mobility | Occasional (5-29%) |
| HP:0002815 | Abnormality of the knee | Occasional (5-29%) |
| HP:0003019 | Abnormality of the wrist | Occasional (5-29%) |
| HP:0003043 | Abnormality of the shoulder | Occasional (5-29%) |
| HP:0005197 | Generalized morning stiffness | Occasional (5-29%) |
| HP:0007663 | Reduced visual acuity | Occasional (5-29%) |
| HP:0012122 | Anterior uveitis | Occasional (5-29%) |
| HP:0025300 | Malar rash | Occasional (5-29%) |
| HP:0025526 | Psoriasiform lesion | Occasional (5-29%) |
| HP:0001094 | Iridocyclitis | Very rare (<1-4%) |
| HP:0001101 | Iritis | Very rare (<1-4%) |
| HP:0001806 | Onycholysis | Very rare (<1-4%) |
| HP:0010754 | Abnormality of the temporomandibular joint | Very rare (<1-4%) |
| HP:0012317 | Sacroiliac arthritis | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | psoriasis-related juvenile idiopathic arthritis |
| Mondo ID | MONDO:0019436 |
| EFO | EFO:0009733 |
| Orphanet | 85436 |
| ICD-11 | 1473955563 |
| NCIT | C114361 |
| SNOMED CT | 239802003 |
| UMLS | C3714758 |
| MedGen | 811463 |
| GARD | 0010970 |
| Is cancer (heuristic) | no |
Also known as: JPsA · juvenile psoriatic arthritis · psoriasis-related JIA
Disease family
This is a subtype of juvenile idiopathic arthritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › connective tissue disorder › rheumatic disorder › juvenile idiopathic arthritis › psoriasis-related juvenile idiopathic arthritis
Related subtypes (5): polyarticular juvenile idiopathic arthritis, oligoarticular juvenile idiopathic arthritis, systemic-onset juvenile idiopathic arthritis, enthesitis-related juvenile idiopathic arthritis, unspecified juvenile idiopathic arthritis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Adalimumab | Approved (phase 4) |
| Risankizumab | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 11.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 7 |
| PHASE1 | 2 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04527380 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis |
| NCT05767047 | PHASE3 | RECRUITING | A Study of Apremilast in Children With Oral Ulcers Associated With Behçet’s Disease or Juvenile Psoriatic Arthritis |
| NCT06100744 | PHASE3 | RECRUITING | A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab |
| NCT06668181 | PHASE3 | RECRUITING | An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis |
| NCT06869551 | PHASE3 | RECRUITING | A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis |
| NCT03031782 | PHASE3 | COMPLETED | Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA) |
| NCT03769168 | PHASE3 | COMPLETED | An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) |
| NCT06751238 | PHASE1 | RECRUITING | Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). |
| NCT05252533 | PHASE1 | COMPLETED | A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis |
| NCT07190053 | Not specified | NOT_YET_RECRUITING | Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry. |
| NCT05545839 | Not specified | COMPLETED | Transition to Adulthood Through Coaching and Empowerment in Rheumatology |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| SECUKINUMAB | 4 | 4 |
| CRAVACITINIB | 4 | 3 |
| APREMILAST | 4 | 1 |
| BIMEKIZUMAB | 4 | 1 |
| IXEKIZUMAB | 4 | 1 |
| RISANKIZUMAB | 4 | 1 |
| CHEMBL475165 | 0 | 1 |
Related Atlas pages
- Drugs: Secukinumab, Cravacitinib, Apremilast, Bimekizumab, Ixekizumab, Risankizumab